Therapeutic Insights
Filter News
Found 299 articles
-
Halberd Corporation's Proprietary Technology for Alzheimer’s Disease Enters Stage 4 of 7 Stage Process
6/21/2021
Halberd Corporation's proprietary technology enters stage 4 to address Alzheimer's Disease (and other potential diseases); eradicating the antibody-disease combination through radiofrequency waves or laser or other means.
-
Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
6/21/2021
Gilead Sciences, Inc. announced that more than 70 abstracts from the company’s liver disease programs will be presented at The International Liver Congress™ 2021 taking place from June 23-26.
-
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
-
Three other drug contenders that work similarly to Biogen’s drug are currently in clinical trials and expecting data relatively soon.
-
Biogen’s quest to develop additional medicines for Alzheimer’s disease beyond its newly-approved aducanumab has hit a clinical snag after gosuranemab failed.
-
Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
6/17/2021
Progenity, Inc. today announced the formation of its Inflammatory Bowel Disease Clinical Advisory Board.
-
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
6/17/2021
Synlogic, Inc. announced today that it has entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic™ medicine for the treatment of inflammatory bowel disease (IBD).
-
Halberd Corporation Successfully Conjugates Metallic Particles and Antibodies Against Alzheimer's Disease-Associated Antigens
6/16/2021
Enables Extracorporeal Eradication of Pathogens from Cerebral Spinal Fluid Via Radio Frequency and/or Laser Emissive Energy
-
New Life-Changing Test for Patients Diagnosed With Peanut Allergy
6/15/2021
AllerGenis announced the publication of a peer-reviewed study entitled, "Accurate and Reproducible Diagnosis of Peanut Allergy Using Epitope Mapping." Conducted by leading global experts in pediatric allergy and immunology from the Icahn School of Medicine at Mount Sinai, Stanford University and Kings College, the study found the AllerGenis peanut diagnostic blood test demonstrates accuracy significantly and statistically superior to all other established diagnostic tests.
-
Investigators from the Cleveland Clinic assessed possible relationships between COVID-19 and neuroinflammation and brain microvascular injury – two hallmarks of AD.
-
Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors
6/14/2021
Cassava Sciences, Inc. today announced the appointment of Mr. Richard (Rick) Barry to the Company’s Board of Directors, effective June 11, 2021.
-
Aaron Kesselheim, a professor of Medicine at Harvard Medical School and has served on the advisory committee since 2015, has stepped down.
-
This is the first confirmation of elemental metals in human brain tissue. Researchers hope it can contribute to the ongoing Herculean task of finding a cure for Parkinson's and Alzheimer's.
-
David S. Knopman and Joel S. Perlmutter both resigned from the committee after the approval of the drug aducanumab.
-
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
6/10/2021
NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's Disease.
-
In a conference call on Wednesday, Biogen CEO Michel Vounatsos outlined the company's plans for commercial distribution of Aduhelm.
-
Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update
6/9/2021
Synaptogenix, Inc. today announced an update on its ongoing National Institutes of Health ("NIH") sponsored Phase 2b clinical trial f Bryostatin-1 in patients suffering from moderately severe Alzheimer's disease.
-
Halberd Corporation Undertakes Process Toward the Elimination of Alzheimer’s Disease
6/9/2021
Halberd Corporation (OTC PINK:HALB) commences experimentations to eradicate three of the principal components of Alzheimer's Disease.
-
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
-
Despite controversy over the drug’s effectiveness, it appears to have spiked interest in investing in Alzheimer’s drug companies, something that had been on the decline for several years.